Connor, Clark & Lunn Investment Management (CC&L)
NDRM

Connor, Clark & Lunn Investment Management (CC&L)’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-13,075
Closed -$391K – 1008
2017
Q2 		$391K Sell
13,075
-2,837
-18% -$73.5K ﹤0.01% 641
2017
Q1 		$422K Buy
+15,912
New +$394K ﹤0.01% 660

Other funds holding NDRM

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CFIC
City Financial Investment Company London, United Kingdom $562M AUM 5.93% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s NDRM Position: Q3 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 13,075 shares — an estimated $391K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NDRM in Q1 2017 and held it in 2 quarters. The position peaked at $422K in Q1 2017. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 13,075 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $391K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NeuroDerm Ltd. Ordinary Shares in Q1 2017 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s NeuroDerm Ltd. Ordinary Shares position peaked at $422K in Q1 2017.
  • 81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2017, filed 14 Nov 2017.